Suppr超能文献

[胰头导管腺癌切除术的结果]

[Results of resection for ductal adenocarcinoma of the pancreatic head].

作者信息

Morin B, Chiche L, Salame E, Lebreton G, Rouleau V, Segol P

机构信息

Service de chirurgie digestive, CHU de la Côte de Nacre, avenue de la Côte de Nacre, 14033 Caen cedex, France.

出版信息

Ann Chir. 2006 Nov;131(9):518-23. doi: 10.1016/j.anchir.2006.04.008. Epub 2006 Jun 14.

Abstract

INTRODUCTION

Pancreaticoduodenectomy (PD) is the only curative treatment for adenocarcinoma of the pancreatic head but is associated with a significant early morbidity and a poor long term survival. Therefore, its value is still debated. The aim of this study was to evaluate early and distant results of PD for pancreatic adenocarcinoma, and to identify prognostic factors.

SUMMARY

Seventy-nine patients who underwent PD with curative intent for adenocarcinoma of the pancreatic head from 1982 to 2002 were studied retrospectively. The following data were evaluated: operative mortality, long-term survival, prognostic factors (through univariate and multivariate analysis), and characteristics of 5-year survivors.

RESULTS

Mortality rate was 1.3%. Survival at 1, 3 and 5 years was 46%, 26% and 11%. The median survival was 12 months. The prognostic factors were the T stage (T.N.M. classification) and radicality of resection. After multivariate analysis, radicality of resection was the only independent prognostic factor. Five patients survived for more than 5 years. They did not differ of the other patients but none had positive margin or venous invasion.

CONCLUSIONS

These results (low mortality, significant distant survival including some long term survivors) suggest that PD for pancreatic adenocarcinoma must be indicated in most low-risk patients. PD remains the only curative treatment allowing prolonged survival.

摘要

引言

胰十二指肠切除术(PD)是胰头腺癌唯一的根治性治疗方法,但该手术早期并发症发生率较高,长期生存率较低。因此,其价值仍存在争议。本研究旨在评估胰十二指肠切除术治疗胰腺腺癌的早期和远期效果,并确定预后因素。

总结

对1982年至2002年间因胰头腺癌接受根治性胰十二指肠切除术的79例患者进行回顾性研究。评估以下数据:手术死亡率、长期生存率、预后因素(通过单因素和多因素分析)以及5年生存者的特征。

结果

死亡率为1.3%。1年、3年和5年生存率分别为46%、26%和11%。中位生存期为12个月。预后因素为T分期(TNM分类)和切除的根治性。多因素分析后,切除的根治性是唯一的独立预后因素。5例患者存活超过5年。他们与其他患者无差异,但均无切缘阳性或静脉侵犯。

结论

这些结果(低死亡率、显著的远期生存包括一些长期生存者)表明,对于大多数低风险患者,必须考虑行胰十二指肠切除术治疗胰腺腺癌。胰十二指肠切除术仍然是唯一能延长生存期的根治性治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验